Pharmacovigilance – Products

Signals One spans the entire “Design-Make-Test-Decide” R&D lifecycle and empowers researchers to address previously “undruggable” targets.

Terumo BCT and KBIOHealth have signed an MOU to develop workforce training for cell and gene therapy manufacturing in Korea. The program will focus on CAR-T and MSC therapy production using automated systems like Quantum Flex.

On February 28, 2025, WHO announced the recommended strains for the 2025-2026 northern hemisphere influenza season.

CN Bio, announced the launch of its PhysioMimix® DILI assay kit: Human 24. Built upon CN Bio’s human-derived and highly characterized liver microphysiological system (MPS).

Lyndra Therapeutics, a clinical-stage biopharmaceutical company, announced a strategic collaboration with Thermo Fisher Scientific Inc.

CN Bio, announced it has entered into a strategic partnership with Japanese life sciences research equipment distributor, Primetech.

Protheragen-ING Lab, a Good Laboratory Practices (GLP) service provider, has recently unveiled its cutting-edge medical device services.

Alfa Chemistry now has an extensive range of products within the pharmaceutical field, including PROTAC building blocks, nucleosides, intermediates and Active Pharmaceutical Ingredients (APIs).

ACROBiosystems offers premium antigens (pre-fusion F, post-fusion F, glycoprotein G) and a Monoclonal Anti-Nipah Antibody for accurate ELISA-based evaluation and vaccine potency studies, supporting Nipah and Hendra virus research.

This interview explores expert insights into cutting-edge methodologies that overcome these challenges, providing actionable insights to optimize vaccine safety and efficacy.